Efficacy of medication for therapeutic angiogenesis in combined treatment of patients with diabetes mellitus and critical limb ischemia

Abstract

The combination of peripheral atherosclerosis and diabetes mellitus is a severe pathology, characterized by a high rate, mortality and social significance. The results of limb salvage and distant survival in this pathology in a remote period are unsatisfactory in spite of all existing treatment methods. Clinical trials in previous years have shown efficacy and safety of the medication, which is a plasmid construct with the gene encoding vascular endothelial growth factor - kambiogenplasmid, in patients with disease stage IIa-III according to the A.V. Pokrovsky and Fontaine classification, who were not indicated for surgical treatment. The article presents the clinical cases of successful use of this drug for therapeutic angiogenesis in patients with critical limb ischemia and severe type 2 diabetes mellitus. The inclusion of therapeutic angiogenesis in the conservative treatment algorithms is promising for the treatment of this group of patients. There is a need for further research on the efficacy and safety of the medication in patients with peripheral atherosclerosis and diabetes mellitus in a remote period.